Best Stocks Under $20.00 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $20.00 (20 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. #1 - JD Sports FashionOTCMKTS:JDSPYStock Price: $2.39 (+$0.04)Average Trading Volume: 2,471 sharesConsensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $203.33 (8,407.7% Upside)JD Sports Fashion Plc retails and distributes sports fashion wear and outdoor clothing and equipment. It operates through the Sports Fashion and Outdoor segments. The Sports Fashion segment consists of JD Sports Fashion Plc, John David Sports Fashion (Ireland) Limited, Spodis SA, Champion Sports Ireland, JD Sprinter Holdings 2010 SL, JD Sports Fashion BV, JD Sports Fashion Germany GmbH, JD Sports Fashion SRL, Duffer of St George Limited, Topgrade Sportswear Limited, Kooga Rugby Limited, Focus Brands Limited, Kukri Sports Limited, Source Lab Limited, R.D. Scott Limited, Tessuti Group Limited, Nicholas Deakins Limited, Cloggs Online Limited, Ark Fashion Limited and Mainline Menswear Limited. The Outdoor segment consists of Blacks Outdoor Retail Ltd. Tiso Group Ltd and ActivInstinct Limited. The company was founded by John Carruthers Wardle and David Martin Makin in 1981 and is headquartered in Bury, the United Kingdom. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Ocular TherapeutixNASDAQ:OCULStock Price: $6.37 (-$0.01)PE Ratio: -5.35Market Cap: $493.87 millionAverage Trading Volume: 1.30 million sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.80 (100.9% Upside)Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.#3 - EveriNYSE:EVRIStock Price: $14.72 (+$0.04)PE Ratio: 12.17Market Cap: $1.31 billionAverage Trading Volume: 747,942 sharesP/E Ratio: 12.2Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $26.20 (78.0% Upside)Everi Holdings, Inc. engages in the provision of technology solutions to the casino, interactive, and gaming industry. It operates through the Games and Financial Technology Solutions (FinTech) segments. The Games segment focuses on leased gaming equipment, sales of gaming equipment, gaming systems, interactive solutions, and ancillary products and services. The FinTech segment provides access to cash at gaming facilities via ATM cash withdrawals, credit card cash access transactions and point of sale debit card cash access transactions, check-related services, fully integrated kiosks and maintenance services, compliance, audit and data software, casino credit data, and reporting services and other ancillary offerings. The company was founded on February 4, 2004 and is headquartered in Las Vegas, NV.#4 - Dyne TherapeuticsNASDAQ:DYNStock Price: $13.16 (-$0.41)PE Ratio: -3.95Market Cap: $767.36 millionAverage Trading Volume: 349,746 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.83 (96.3% Upside)Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..#5 - InflaRxNASDAQ:IFRXStock Price: $4.37 (-$0.38)PE Ratio: -7.05Market Cap: $195.34 millionAverage Trading Volume: 1.66 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.00 (220.4% Upside)InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.#6 - Avidity BiosciencesNASDAQ:RNAStock Price: $10.69 (-$0.32)PE Ratio: -3.18Market Cap: $757.07 millionAverage Trading Volume: 1.15 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $42.60 (298.5% Upside)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.#7 - Energy TransferNYSE:ETStock Price: $12.72 (+$0.19)PE Ratio: 9.49Market Cap: $39.96 billionAverage Trading Volume: 12.16 million sharesP/E Ratio: 9.5Dividend Yield: 9.87%Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $16.43 (29.2% Upside)Energy Transfer LP provides natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acq#8 - CymaBay TherapeuticsNASDAQ:CBAYStock Price: $9.05 (-$0.11)PE Ratio: -7.67Market Cap: $882.47 millionAverage Trading Volume: 1.65 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.57 (61.0% Upside)CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.#9 - 89bioNASDAQ:ETNBStock Price: $16.91 (-$0.73)PE Ratio: -6.00Market Cap: $1.23 billionAverage Trading Volume: 1.81 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $34.00 (101.1% Upside)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.#10 - Atlas Energy SolutionsNYSE:AESIStock Price: $17.54 (+$0.03)Market Cap: $1.75 billionAverage Trading Volume: 481,299 sharesDividend Yield: 0.86%Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $24.44 (39.4% Upside)Atlas Energy Solutions Inc. is a provider of proppant and logistics services to customers engaged in the oil and natural gas industry principally within the Permian Basin of West Texas and New Mexico. Atlas Energy Solutions Inc. is based in AUSTIN, Texas.#11 - Thorne HealthTechNASDAQ:THRNStock Price: $4.38 (-$0.11)PE Ratio: 23.05Market Cap: $235.91 millionAverage Trading Volume: 48,069 sharesP/E Ratio: 23.1Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.92 (57.9% Upside)Thorne HealthTech, Inc., a science-driven wellness company, provides solutions and personalized approaches to health and wellness in the United States and internationally. It offers various health tests, such as sleep, stress, weight management, gut health, heavy metals, biological age, and other health tests that generate molecular portraits for its customers, as well as develops nutritional supplements and offers wellness education solutions. The company uses the Onegevity platform to map, integrate, and understand the biological features that describe the state of an individual's health, as well as provide actionable insights and personalized data, products, and services that help individuals to take a proactive approach to improve and maintain their health. It primarily serves healthcare professionals, professional athletes, and professional sports and Olympic teams. Thorne HealthTech, Inc. was founded in 1984 and is headquartered in New York, New York.#12 - SaipemOTCMKTS:SAPMYStock Price: $0.29 (+$0.02)PE Ratio: 0.89Average Trading Volume: 41,713 sharesP/E Ratio: 0.9Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.95 (584.2% Upside)Saipem SpA provides integrated basic and detailed onshore engineering, procurement, project management, and construction services mainly to the oil and gas, complex civil and marine infrastructure, and environmental market sectors. It operates through the following business segments: Offshore Engineering and Construction; Onshore Engineering and Construction; Offshore Drilling; and Onshore Drilling. The Offshore Engineering and Construction segment includes platforms, pipelines, subsea field developments, MMO or Maintenance, Modification, and Operations activities, and the execution of large-scale offshore projects. The Onshore Engineering and Construction segment designs and constructs hydrocarbon production facilities, hydrocarbon treatment facilities, and large onshore treatment and transportation systems and facilities. The Offshore Drilling segment consists of a fleet of vessels for deep water, mid-water, high specifications jack-up, and standard jack-up operations. The Onshore Drilling segment comprises a fleet of drilling rigs for wells in Italy and abroad. The company was founded in 1957 and is headquartered in San Donato Milanese, Italy.#13 - HarmonicNASDAQ:HLITStock Price: $16.83 (+$0.28)PE Ratio: 54.29Market Cap: $1.87 billionAverage Trading Volume: 1.38 million sharesP/E Ratio: 54.3Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $20.17 (19.8% Upside)Harmonic, Inc. engages in the development and sale of video delivery software, products, system solutions, and services. It operates through the Video and Cable Access segments. The Video segment sells video processing and production and playout services to cable operators, satellite and telecommunications pay-TV service providers, and broadcast and media companies. The Cable Access segment offers solutions to cable operators. The company was founded in June 1988 and is headquartered in San Jose, CA.#14 - Integra ResourcesNYSEMKT:ITRGStock Price: $0.49 (-$0.01)PE Ratio: -1.67Market Cap: $39.08 millionAverage Trading Volume: 105,321 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.58 (432.0% Upside)Integra Resources Corp., a mineral resources company, engages in the acquisition, exploration, and development of mineral properties in the Americas. It primarily focuses on the development of DeLamar project that consists of DeLamar and Florida Mountain gold and silver deposits comprising 790 unpatented lode, placer, and millsite claims, as well as 16 tax parcels covering an area of approximately 8,673 hectares located in the Owyhee County, south western Idaho. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.#15 - CarParts.comNASDAQ:PRTSStock Price: $4.34 (-$0.11)PE Ratio: -108.50Market Cap: $244.47 millionAverage Trading Volume: 722,494 sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.00 (176.5% Upside)CarParts.com, Inc. operates as an online provider of aftermarket auto parts and accessories in the United States and the Philippines. Its products include Collision Parts, Engine Parts, Performance Parts and Accessories. The firm also sells auto parts to collision repair shops, markets Kool-Vue products to auto parts wholesale distributor, and aftermarket catalytic converters under the Evan Fischer brand. Its flagship Websites include www.carparts.com, www.jcwhitney.com, www.autopartswarehouse.com and www.usautoparts.com. The company was founded by Sol Khazani and Mehran Nia in 1995 and is headquartered in Carson, CA.#16 - Crombie Real Estate Investment TrustOTCMKTS:CROMFStock Price: $11.21PE Ratio: -25.26Average Trading Volume: 412 sharesDividend Yield: 7.46%Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.30 (63.2% Upside)Crombie Real Estate Investment Trust operates as an open-ended real estate investment trust. It invests in retail stores, offices, and commercial mixed-use buildings. It also acquires grocery and drug store anchored retail properties. The company was founded on January 1, 2006 and is headquartered in New Glasgow, Canada.#17 - Mineralys TherapeuticsNASDAQ:MLYSStock Price: $15.86 (-$0.16)Market Cap: $648.04 millionAverage Trading Volume: 186,470 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $36.20 (128.2% Upside)Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.#18 - SilverCrest MetalsNYSEMKT:SILVStock Price: $6.78 (-$0.12)PE Ratio: 15.07Market Cap: $998.23 millionAverage Trading Volume: 901,689 sharesP/E Ratio: 15.1Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.70 (72.6% Upside)SilverCrest Metals Inc. explores for and develops precious metal properties in Mexico. The company primarily explores for silver and gold properties. Its principal property includes the Las Chispas project that consists of 28 concessions totaling of approximately 1,401 hectares located in Sonora, Mexico. The company was incorporated in 2015 and is headquartered in Vancouver, Canada.#19 - Caribou BiosciencesNASDAQ:CRBUStock Price: $4.26 (-$0.13)PE Ratio: -2.39Market Cap: $261.39 millionAverage Trading Volume: 507,043 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $27.60 (547.9% Upside)Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.#20 - EngageSmartNYSE:ESMTStock Price: $17.80PE Ratio: 136.93Market Cap: $2.97 billionAverage Trading Volume: 500,833 sharesP/E Ratio: 136.9Consensus Rating: Buy (6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.88 (45.4% Upside)EngageSmart, Inc. provides Software-as-a-Service based customer engagement software and integrated payment solutions. It operates through two segments, Enterprise Solutions and SMB (small and medium sized business) Solutions. The company offers SimplePractice, an end-to-end practice management and electronic health record platform for health and wellness professionals to manage their practices; and InvoiceCloud, an electronic bill presentment and payment solution that helps government, utility, and financial services customers to digitize billing, client communications, and collections. It also provides HealthPay24, a patient engagement and payment platform that helps health systems, physician groups, dental practices, and medical billers to drive patient self-pay collections; and DonorDrive, a fundraising software platform that helps non-profits, healthcare organizations, and higher education institutions produce virtual events, launch branded donation campaigns, and create peer-to-peer fundraising experiences. The company was formerly known as EngageSmart, LLC. and changed its name to EngageSmart, Inc. in June 2021. EngageSmart, Inc. was incorporated in 2018 and is headquartered in Braintree, Massachusetts.#21 - SSR MiningNASDAQ:SSRMStock Price: $15.75 (-$0.35)PE Ratio: 21.88Market Cap: $3.32 billionAverage Trading Volume: 1.60 million sharesP/E Ratio: 21.9Dividend Yield: 1.72%Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $26.67 (69.3% Upside)SSR Mining, Inc. is a gold company, which engages in the operation, development, exploration, and acquisition of metal resource properties. It operates through the following business segments: Copler, Marigold, Seabee, Puna and the Exploration, Evaluation, and Development Properties. The Copler, Marigold, Seabee, and Puna segment represent its four operating mine sites. The Exploration, Evaluation, and Development Properties segment includes a portfolio of prospective exploration tenures. The company was founded on December 11, 1946 and is headquartered in Denver, CO.#22 - First Capital Real Estate Investment TrustOTCMKTS:FCXXFStock Price: $11.39Average Trading Volume: 1,042 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $19.57 (71.8% Upside)First Capital is a leading developer, owner and manager of mixed-use real estate located in Canada's most densely populated cities. First Capital's focus is on creating thriving urban neighbourhoods to generate value for businesses, residents, communities and our investors.#23 - Fusion PharmaceuticalsNASDAQ:FUSNStock Price: $4.25 (-$0.12)PE Ratio: -2.14Market Cap: $271.36 millionAverage Trading Volume: 266,212 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.67 (103.9% Upside)Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.#24 - Topgolf Callaway BrandsNYSE:MODGStock Price: $17.46 (-$0.49)PE Ratio: 37.15Market Cap: $3.24 billionAverage Trading Volume: 1.79 million sharesP/E Ratio: 37.1Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $31.50 (80.4% Upside)Topgolf Callaway Brands Corp. engages in the manufacture and distribution of golf equipment and accessories. It operates through the Golf Equipment and Apparel, Gear, and Other segments. The Golf Equipment segment focuses on the design, manufacture, and sale of a full line of golf equipment. The Apparel, Gear, and Other segment refers to the development and sale of soft goods under the Callaway, TravisMathew, OGIO, and Jack Wolfskin brands. The company was founded by Ely Reeves Callaway, Jr. in 1982 and is headquartered in Carlsbad, CA.#25 - MVB FinancialNASDAQ:MVBFStock Price: $17.39 (-$0.23)PE Ratio: 9.61Market Cap: $220.85 millionAverage Trading Volume: 44,499 sharesP/E Ratio: 9.6Dividend Yield: 4.05%Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $28.40 (63.3% Upside)MVB Financial Corp. is a holding company, which through its subsidiary, engages in the provision of community and mortgage banking services. It also offers commercial and consumer loans, offering an array of loan products for commercial development and real estate, capital needs, as well as personal loans, residential real estate loans, home equity lines of credit, and construction mortgages. The company was founded in 1997 and is headquartered in Fairmont, WV. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks Electric Vehicle Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Cheap Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $3.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: It’s Time To Take Another Bite Of Take-Two Interactive Zoetis Declares New Dividend, Hinting At UndervaluationGood News For Walmart Isn’t So Great For Everybody ElseEagle Materials, Answering America's Building Supply NeedsCopart Auctions, A Little Outlet For America's Car ProblemsVertex Pharmaceuticals Hits Record High on Strong Q1 EarningsBerry Global, The Backbone Of Consumer Packaging You Should OwnPharma Giants Novartis, Lilly, Merck, and Novo Outperform Market Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.